Drug metabolism and atypical antipsychotics
Authors:
- Trevor I PriorTPTrevor I Prior
- Pierre S ChuePCPierre S Chue
- Philip TibboPTPhilip Tibbo
- Glen B BakerGBGlen B Baker
- 1 June 1999
- journal article
- review article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 9 (4) , 301-309
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitorsAmerican Journal of Psychiatry, 1996
- Pharmacokinetics of Clozapine and RisperidoneJournal of Clinical Psychopharmacology, 1996
- Erythromycin-induced clozapine toxic reactionArchives of internal medicine (1960), 1996
- Cytochrome P4502D6 genotype does not determine response to clozapine.British Journal of Clinical Pharmacology, 1995
- The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects.British Journal of Clinical Pharmacology, 1995
- Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.British Journal of Clinical Pharmacology, 1994
- Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproateAmerican Journal of Psychiatry, 1994
- Disposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.British Journal of Clinical Pharmacology, 1994
- Isoniazid InteractionsSouthern Medical Journal, 1985